The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-Synuclein Post-Translational Modifications Quantification Program, 2025SUPPLEMENT: Spatially Resolved Proteomics for Quantitative Mapping of Post-Translational Modifications of Alpha-synuclein
Study Rationale: Alpha-synuclein is the key protein involved in Parkinson’s disease (PD). In the process of the disease, it loses its proper shape and clumps together. These clumps are toxic to cells...
-
Research Grant, 2025SUPPLEMENT: Empowering Community Health Workers in Clinical Research: A Proposal to Enhance the MJFF Clinical Research Training Modules with Multimedia for Greater Impact
The NYU Clinical and Translational Science Institute (CTSI), in collaboration with The Michael J. Fox Foundation, is developing an online, asynchronous, module-based community health worker (CHW)...
-
Research Grant, 2025SUPPLEMENT: Cytokine Production by Adaptive Immune Cells from Patients with Parkinson’s Disease: Response to Diverse Biological Stimuli
Study Rationale: Studies demonstrate a role for the adaptive immune system (T-cells and B-cells) in PD. The rationale for this study is that by using enriched T-cells and B-cells and exposing the...
-
Research Grant, 2025First-in-human Evaluation of [11C]UCB-1A as Imaging Marker for Vesicle Glycoprotein 2C (SV2C): a PET Study in Healthy Volunteers and in Subjects with Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) damages brain connections early on, linked to accumulation of a protein called alpha-synuclein. We aim to track this accumulation using a new brain imaging...
-
T2T Validation - NOD2, 2025Assessing the Role Played by NOD2 in Murine Models of PD
Study Rationale: Brain inflammation has been associated with the development of Parkinson’s disease (PD). In search for factors that may influence inflammation that triggers PD, several groups have...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025SUPPLEMENT: A Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: There is currently no treatment that slows or stops the progression of Parkinson’s disease (PD). We are developing a novel therapeutic approach that targets neuroinflammation and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.